The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

NCT01220570 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Ridaforolimus + Dalotuzumab
DRUG: Ridaforolimus
DRUG: Dalotuzumab

Sponsor

Merck Sharp & Dohme LLC